5M0B.F · Medicover AB (publ)

-

Please sign in to comment on 5M0B.F

1 Comment

Admin

3 years, 7 months ago

Medicover AB (publ) is currently in a long term uptrend where the price is trading 33.9% above its 200 day moving average.

From a valuation standpoint, the stock is 99.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 2.6.

Medicover AB (publ)'s total revenue rose by 29.6% to $298M since the same quarter in the previous year.

Its net income has increased by 180.0% to $18M since the same quarter in the previous year.

Finally, its free cash flow grew by 2800.0% to $8M since the same quarter in the previous year.

Based on the above factors, Medicover AB (publ) gets an overall score of 5/5.

Industry	Medical Care Facilities
Sector	Healthcare
ISIN	SE0009778848
CurrencyCode	EUR
Exchange	F

Beta	1.46
Dividend Yield	0.8%
Target Price	None
PE Ratio	200.12
Market Cap	2B

ABOUT

Medicover AB (publ)

Medicover AB (publ) provides healthcare and diagnostic services in Poland, Germany, Romania, India, Sweden, Turkey, Belarus, Bulgaria, Georgia, Hungary, Serbia, Moldova, Ukraine, and India. It operates through two segment, Healthcare Services and Diagnostic Services. The company's diagnostic services comprise various tests, including allergy and autoimmune diagnostics, bacteriology, parasitology, biochemistry and immunochemistry, blood group diagnostics/transfusion medicine, tumour markers, clinical chemistry, cytology, haematology, histopathology, human genetics, hygiene, immunology and immunochemistry, infectious diseases, microbiology, molecular biology, and pharmacology/toxicology. It serves corporate and private customers, and patients, as well as public payers. Medicover AB (publ) was founded in 1995 and is headquartered in Stockholm, Sweden.

5M0B.F · Medicover AB (publ)

-

Medicover AB (publ)

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Medicover AB (publ) using a moving average strategy